Search results for: rare disease

Germany: Experts criticise the GKV’s financial s...

On 28th September there was a two-hour public hearing on the GKV Financial Stabilisation Act. There ...

Pricing and reimbursement of cell and gene therapi...

Introduction The European landscape has seen both approvals and withdrawals of cell and gene therapi...

Are payers willing to pay for innovation for gene ...

We look at whether payers are willing to pay for innovative gene therapies & CAR-Ts and the impact o...

HTA/Payer Early Dialogue

PMA Insights: Week 26

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

What is the New Innovative Medicines Fund and What...

The Innovative Medicines Fund launched on 7th June 2022 The Innovative Medicines Fund (IMF), which w...

New pilot project which delays reimbursement for o

Under ODAP, a protocol is drawn up “with criteria for starting, stopping and effect of a medicine....

What do France’s ATU reforms mean for manufa...

Introduction On 1 July 2021, France made changes to its long-standing Authorization for Temporary Us...

Innovation and affordability of orphan drugs

The paper examines potential reforms to current policies and practices related to orphan drug develo...

How do you win the race to market? Our top conside...

Introduction Early Access Programs, also known as special access programs, give patients access to m...